Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity. PS315 is a derivative of PS48 and is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing displacement of the active site residue Lys111.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity. PS315 is a derivative of PS48 and is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing displacement of the active site residue Lys111. |
Targets&IC50 | PKCη:30 μM, PKCζ:10 μM |
In vitro | PS315, by attaching to the PIF-pocket, prompts a shift in the active site residue Lys111, effectively inhibiting aPKCs through an allosteric impact on the enzyme's catalytic process. A pre-treatment of U937 cells with 5 μM PS315 results in a 74% reduction in TNF-α-induced NF-κB activation, with total inhibition achieved at 10 μM PS315. The allosteric inhibitor PS315, along with the N-terminal region of aPKC, directly influences the PIF-pocket on-off switch[1]. |
Molecular Weight | 362.85 |
Formula | C23H19ClO2 |
CAS No. | 1221964-50-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PS315 1221964-50-6 Chromatin/Epigenetic Cytoskeletal Signaling PKC PS 315 PS-315 inhibitor inhibit